Black Rock Inc. Astria Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,517,580 shares of ATXS stock, worth $32.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,517,580

Previous 3,585,493 1.89%

Holding current value

$32.2 Million

Previous $50.4 Million 36.55%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$8.83 - $13.51 $599,671 - $917,504	-67,913 Reduced 1.89%	3,517,580 $32 Million
Q1 2024 May 10, 2024	BUY	$6.99 - $16.69 $9.79 Million - $23.4 Million	1,400,935 Added 64.13%	3,585,493 $50.4 Million
Q4 2023 Feb 13, 2024	BUY	$4.42 - $8.06 $2.19 Million - $4 Million	495,722 Added 29.35%	2,184,558 $16.8 Million
Q3 2023 Nov 13, 2023	BUY	$6.89 - $9.86 $250,286 - $358,174	36,326 Added 2.2%	1,688,836 $12.6 Million
Q2 2023 Aug 11, 2023	BUY	$8.33 - $13.72 $11.4 Million - $18.7 Million	1,364,141 Added 473.05%	1,652,510 $13.8 Million
Q1 2023 May 12, 2023	BUY	$11.2 - $15.79 $2.2 Million - $3.11 Million	196,770 Added 214.82%	288,369 $3.84 Million
Q4 2022 Feb 13, 2023	BUY	$7.44 - $14.89 $98,758 - $197,649	13,274 Added 16.95%	91,599 $1.36 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $10.34 $50,097 - $174,415	16,868 Added 27.45%	78,325 $708,000
Q2 2022 Aug 12, 2022	BUY	$2.46 - $6.96 $27,234 - $77,054	11,071 Added 21.97%	61,457 $185,000
Q1 2022 May 12, 2022	SELL	$3.92 - $7.1 $10,533 - $19,077	-2,687 Reduced 5.06%	50,386 $338,000
Q4 2021 Feb 10, 2022	BUY	$5.08 - $8.62 $60,741 - $103,069	11,957 Added 29.08%	53,073 $287,000
Q3 2021 Nov 09, 2021	BUY	$7.32 - $12.9 $300,969 - $530,396	41,116 New	41,116 $363,000

Others Institutions Holding ATXS

# of Institutions

107

Shares Held

48.6M

Call Options Held

48K

Put Options Held

9.3K

View Full List

About Astria Therapeutics, Inc.

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $139M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

More about ATXS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account